

## Thorney Investment Group Becomes a Substantial Strategic Investor

23 September 2020

- Thorney Investment Group increases its existing holding to become a substantial shareholder in Zelira Therapeutics rising to a 5.2% stake
- \$2 million private placement strengthens Zelira's financial position
- Secures a successful institutional investor as a substantial shareholder
- Funds will be used to accelerate commercialisation
- Part of a deliberate strategy to increase institutional ownership of the company

Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF) is pleased to announce it has secured a \$2 million strategic investment from the Thorney Investment Group resulting in Thorney becoming a substantial shareholder in the Company with a 5.2% stake.

Under the private placement to institutional investor Thorney, the Company will issue 37,037,000 new shares at an issue price of A\$0.054 per share (New Shares). This price represents a discount of 11.8% of the 15-day volume weighted average price (VWAP).

Furthermore, subject to shareholder approval at Zelira's Annual General Meeting in November, the Company will issue Thorney a one-for-one free attaching unquoted option, exercisable at A\$0.07 and expiring two years from the date of issue.

**Alex Waislitz, Chairman of Thorney Investment Group** said *"While the global medicinal cannabinoid sector has many entrants, we believe Zelira is well placed with its life science approach to take advantage of multiple opportunities in multiple jurisdictions. The strategic focus on intellectual property protection, together with its capital light business model we believe positions the company strongly as it commences revenue generation."*

**Zelira's Chairman, Osagie Imasogie**, said, *"Zelira is delighted to welcome Thorney Investment Group as a substantial investor in the Company. With a strong balance sheet and a supportive strategic partner, Zelira is well positioned to accelerate its path to commercialisation in global markets."*

The issue of the 37,037,000 New Shares is not subject to shareholder approval as the issuance will fall within the Company's placement capacity pursuant to ASX Listing Rule 7.1A. The new Ordinary Shares will

rank pari passu with the existing ordinary shares in the Company. The issue price of the Placement of A\$0.054 per Share meets the requirement of ASX Listing Rule 7.1A.3, being greater than 75% of the 15-day volume weighted average price (VWAP).

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.

**Richard Hopkins**  
**CEO & Managing Director ex-USA**

**About Zelira Therapeutics ([www.zeliratx.com](http://www.zeliratx.com))**

Zelira Therapeutics Ltd is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions including insomnia, autism and chronic non-cancer pain.

The Company has two proprietary formulations under the HOPE™ brand that are generating revenues in Pennsylvania and have been licensed in Louisiana with other states in the US expected to follow. Zelira has also developed Zenivol™ - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol™ has successfully completed the world's first Phase 2a clinical trial for chronic insomnia where it was found to be a safe and effective treatment. Zenivol™ was successfully launched in Sept 2020.

The Company conducts its work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

**Address**

Level 26  
140 St Georges Terrace  
Perth WA 6000  
AUSTRALIA  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
E: [enquiries@zeliratx.com](mailto:enquiries@zeliratx.com)  
W: [www.zeliratx.com](http://www.zeliratx.com)  
ACN 103 782 378

**Australia Contacts:**

Dr Richard Hopkins  
Managing Director & CEO, Ex USA  
+61 405 656 868  
[rhopkins@zeliratx.com](mailto:rhopkins@zeliratx.com)  
Level 26, 140 St Georges Terrace  
Perth WA 6000  
AUSTRALIA

**U.S. Contacts:**

Dr Oludare Odumosu  
Managing Director & CEO, USA  
+1 909 855 0675  
[oodumosu@zeliratx.com](mailto:oodumosu@zeliratx.com)  
5110 Campus Drive, Suite 150  
Plymouth Meeting, PA 19462  
UNITED STATES OF AMERICA

**Tickers**

Australia (ASX): ZLD  
USA (OTCQB): ZLDAF

**Monsoon Communications**

Rudi Michelson  
+61 3 9620 3333  
[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

**GVM Communications, Inc.**

Gia Morón  
+1 347 678 8079  
[gia@gvmcommsinc.com](mailto:gia@gvmcommsinc.com)